Showing posts with label a/h1n2. Show all posts
Showing posts with label a/h1n2. Show all posts

Thursday, April 9, 2026

Genetic characterization of a novel triple - #reassortant #influenza #H1N2 virus from #pigs, #China, 2021

 


Abstract

Swine influenza virus (SIV) is a highly contagious respiratory pathogen in pigs, with bidirectional transmission posing a potential threat to human health. In this study, nasal swab samples were collected from pigs in Shandong Province, China, and yielded an H1N2 SIV strain, designated A/swine/Shandong/QD726/2021 (H1N2). Whole-genome sequencing was performed for Sw/SD/QD726/2021, and phylogenetic analysis was conducted together with 156 Chinese H1N2 reference sequences obtained from the Global Initiative on Sharing All Influenza Data (GISAID) database and the National Center for Biotechnology Information (NCBI) Influenza Virus Resource database. The results indicated that Sw/QD726/2021 represents a novel reassortant genotype (G21), with the HA gene derived from Eurasian avian-like H1N1 (EA H1N1), the NA and NS genes from triple-reassortant H1N2 (TR H1N2), and the remaining internal genes (PB2, PB1, PA, NP, M) from the 2009 pandemic H1N1 (pdm/09 H1N1). Key amino acid analysis revealed N31 in M2, responsible for adamantane resistance, and S42 in NS1, which influences viral virulence in mouse models. BALB/c mouse experiments demonstrated efficient viral replication in the lungs and nasal turbinates, accompanied by moderate body weight loss and lung lesions, indicating only moderate pathogenicity. These findings underscore the ongoing evolution of H1N2 SIV in pigs and emphasize the importance of enhanced surveillance and preventive strategies to mitigate public health risks.

Source: 


Link: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2026.1779293/full

____

Thursday, February 19, 2026

Impact of an #aminoacid #deletion detected in the #hemagglutinin (HA) #antigenic site of swine #influenza A virus field strains on HA antigenicity

 


ABSTRACT

Swine influenza A virus (swIAV) is an important pathogen with regard to both the swine industry and public health. The pandemic A(H1N1) 2009 outbreak was caused by the swine-origin pandemic A(H1N1) 2009 [A(H1N1)pdm09] virus. Several reports have shown that several amino acid substitutions in the hemagglutinin (HA) antigenic sites can alter HA antigenicity. However, the impact of the amino acid deletion at position 155 on HA antigenicity remains unknown. In this study, we have isolated 11 samples of swIAVs from seven pig farms in Japan and found an amino acid deletion at position 155 of the HA region in one of the isolates of the H1N2 subtype. To examine the impact of this amino acid deletion on viral replication and HA antigenicity, we generated recombinant influenza A viruses possessing the H1 HA gene encoding either an artificial insertion or deletion of glycine at position 155. The growth kinetics of these recombinant viruses in two different cell lines demonstrated that the effect of amino acid deletion at position 155 of H1 HA on viral replication is limited. In contrast, microneutralization assay-based neutralization titers revealed that amino acid deletion significantly altered HA antigenicity. These results demonstrate that a naturally occurring amino acid deletion at position 155 in an H1 HA antigenic site can markedly alter HA antigenicity with only a limited impact on replication in vitro, highlighting the need to monitor such variants in swine populations and to assess their zoonotic potential.

Source: 


Link: https://journals.asm.org/doi/full/10.1128/jvi.01820-25?af=R

____

Monday, December 22, 2025

#Influenza at the #human - #animal #interface - Summary and #risk #assessment, from 6 November to 19 December 2025 (#WHO, edited)

 


Influenza at the human-animal interface 

Summary and risk assessment, from 6 November to 19 December 2025 {1}


-- New human cases {1,2}: 

- From 6 November to 19 December 2025, based on reporting date, the detection of influenza A(H5N1) in one human, A(H5N5) in one human, A(H9N2) in seven humans, and an influenza A(H1N1) variant virus in one human were reported officially. 

- In addition, one human case of infection with an influenza A(H1N2) variant virus was detected. 


-- Circulation of influenza viruses with zoonotic potential in animals

- High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3} 

- The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 

- Additionally, low pathogenicity avian influenza viruses as well as swine influenza viruses continue to circulate in animal populations. 


-- Risk assessment {5}: 

- Sustained human to human transmission has not been reported associated with the above-mentioned human infection events. 

- Based on information available at the time of this risk assessment update, the overall public health risk from currently known influenza A viruses detected at the human-animal interface has not changed and remains low

- The occurrence of sustained human-to-human transmission of these viruses is currently considered unlikely

- Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  


-- IHR compliance {6}: 

- This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin (HA) gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. 

- Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.  


Avian influenza viruses in humans 

-- Current situation:  

- Since the last risk assessment of 5 November 2025, one laboratory-confirmed human case of A(H5N1) infection was detected in Cambodia, and one laboratory-confirmed human case of A(H5N5) virus infection was detected in the United States of America


A(H5N1), Cambodia 

- On 16 November 2025, Cambodia notified WHO of a confirmed human infection with avian influenza A(H5N1) in a 22-year-old male from Phnom Penh

- The case developed symptoms on 10 November 2025, sought medical care at a clinic, and was diagnosed with pneumonia. 

- He was subsequently admitted to the national hospital in Phnom Penh on 13 November. 

- Samples were collected on the same day and tested positive for avian influenza A(H5N1) on 15 November. 

- His condition deteriorated rapidly, and he died the same day.   

- Investigations conducted in the case's hometown in Kampong Cham Province, which he visited between 4 and 6 November, revealed that the case had apparently healthy domestic birds (chickens and ducks) in his house. 

- However, sick and dead poultry had been reported in the village since 15 October

- Samples collected from two ducks and one chicken in the village tested positive for influenza A(H5N1). 

- Enhanced public health surveillance was implemented. 

- Among the case’s contacts, one was symptomatic, and all contacts tested negative for influenza A(H5N1).  

- Eighteen human infections with A(H5N1) viruses have been confirmed in Cambodia in 2025 and nine of these have been fatal

- All these cases in 2025 had exposure to domestic birds or their environments. 

- In some cases, domestic birds were reported to be sick or dead. 

- Where the information is available, the genetic sequence data from the viruses from the human cases closely matches that from recent local animal viruses and are identified as clade 2.3.2.1e viruses

- From the information available thus far on these recent human cases, there is no indication of human-tohuman transmission of the A(H5N1) viruses.  


A(H5N5), United States of America 

- On 15 November 2025, the United States of America (US) notified WHO of a confirmed human infection with influenza A(H5). 

- The patient was an adult with underlying medical conditions residing in Washington State

- The patient developed symptoms including fever during the week ending 25 October 2025. 

- During the week ending 8 November 2025, the patient was hospitalized with a serious illness and subsequently died on 21 November.  

- Respiratory specimens collected at the healthcare facility tested positive for influenza A virus by reverse-transcription-polymerase chain reaction (RT-PCR) and were presumptive positive for influenza A(H5) at the laboratory at the University of Washington. 

- The specimens were sent to the Washington State Public Health Laboratory, where influenza A(H5) was confirmed with the US Centers for Disease Control and Prevention (CDC) influenza A(H5) assay. 

- The sample was received at the CDC on 19 November. Sequencing conducted at the University of Washington and at the CDC indicated this was an influenza A(H5N5) virus belonging to the H5 haemagglutinin (HA) clade 2.3.4.4b.  

- Public health investigation revealed that the patient kept backyard poultry and domestic birds. 

- Additional epidemiological investigations were under way at the time of notification and included active monitoring of anyone who was in close contact with the patient.{7,8} 

- This is the first human case of this subtype reported globally. 

- Human infections with A(H5N1), A(H5N2), A(H5N6) and A(H5N8) have been reported previously. 

- A(H5N5) virus infections in animals have been detected and reported. 

- HPAI A(H5) clade 2.3.4.4b A(H5N5) viruses have been detected in North America in wild birds and wild mammals since at least 2023.{9} 

- According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in Africa, the Americas, Asia and Europe

- Infections in non-human mammals are also reported, including in marine and land mammals.{10} 

- A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{11}


-- Risk Assessment for avian influenza A(H5) viruses:  

1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?  

- Most human infections so far have been reported in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. 

- As long as the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but remain unusual. 

- The impact for public health if additional sporadic cases are detected is minimal

- The current overall global public health risk of additional sporadic human cases is low


2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H5) viruses related to the events above?  

- No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5) viruses. 

- There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. 

- In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.  

- Current evidence suggests that influenza A(H5) viruses related to these events did not acquire the ability to efficiently transmit between people, therefore sustained human-to-human transmission is thus currently considered unlikely.  


3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?  

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

- If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


A(H9N2), China  

- Since the last risk assessment of 5 November 2025, China notified WHO of four cases of infection with influenza A(H9N2) on 6 November 2025 and three cases on 12 December 2025. 

- All but two cases were in children

- Cases were detected in Guangdong (one), Guangxi (three), Henan (one) and Hubei (two) provinces. 

- The cases had onsets of symptoms in September, October and November 2025. 

- Four cases had reported exposure to backyard poultry, two had exposure to live poultry markets and the source of exposure for one case was under investigation at the time of reporting. 

- All cases had mild illness and recovered, except one in an elderly person with underlying conditions who was hospitalized at the time of reporting with severe pneumonia. 

- No further cases were detected among contacts of these cases. 

- A(H9) viruses were detected in environmental samples collected during the investigations around some of the cases. 


-- Risk Assessment for avian influenza A(H9N2):   

- 1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?   

- Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments. 

- Most human infections of A(H9N2) to date have resulted in mild clinical illness

- Since the virus is endemic in poultry in multiple countries in Africa and Asia, further human cases associated with exposure to infected poultry are expected but remain unusual. 

- The impact to public health if additional sporadic cases are detected is minimal

- The overall global public health risk of additional sporadic human cases is low.  


2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses related to this event?   

- At the present time, no sustained human-to-human transmission has been identified associated with the recently reported human infections with A(H9N2) viruses. 

- Current evidence suggests that A(H9N2) viruses from these cases did not acquire the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.   


3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?   

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

- If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.   


Swine influenza viruses in humans 

Influenza A(H1N1)v, China 

- Since the last risk assessment of 5 November 2025, the detection of a Eurasian avian-like swine influenza A(H1N1)v virus in a human was reported from China on 12 December 2025. 

- A 60-year-old male from Yunnan province had onset of mild illness on 2 November 2025, was hospitalized on 6 November and discharged on 10 November. 

- He had reported exposure to backyard pigs


Influenza A(H1N2)v, USA 

- A human case of infection with an influenza A(H1N2)v virus was detected in the state of Vermont in an adult who had an onset of symptoms in early October. 

- The individual was briefly hospitalized and has recovered. 

- The investigation conducted by state public health officials was unable to determine the likely source of exposure or if close contacts developed symptoms. 

- According to the report, no human-to-human transmission was identified associated with this case.{12}  


-- Risk Assessment:  

1. What is the public health risk of additional human cases of infection with swine influenza viruses?  

- Swine influenza viruses circulate in swine populations in many regions of the world. 

- Depending on geographic location, the genetic characteristics of these viruses differ. 

- Most human cases are exposed to swine influenza viruses through contact with infected animals or contaminated environments. 

- Human infection tends to result in mild clinical illness in most cases. 

- Since these viruses continue to be detected in swine populations, further human cases are expected. 

- The impact to public health if additional sporadic cases are detected is minimal

- The overall risk of additional sporadic human cases is low.  


2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses?   

- No sustained human-to-human transmission was identified associated with the events described above. 

- Current evidence suggests that contemporary swine influenza viruses have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely. 


3. What is the likelihood of international spread of swine influenza viruses by travelers?   

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

- If this were to occur, further community level spread is considered unlikely as current evidence suggests that these viruses have not acquired the ability to transmit easily among humans. 


Overall risk management recommendations

-- Surveillance and investigations

Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published guidance on surveillance for human infections with avian influenza A(H5) viruses

As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

Countries should increase avian influenza surveillance in: 

- domestic and wild birds,

- enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, 

- include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; 

- monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, 

- share genetic sequences of avian influenza viruses in publicly available databases, 

- implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, 

- employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{13} 

- More guidance can be found from WOAH and FAO

- When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. 

- Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: 

> enhanced surveillance in local influenza-like illness (ILI)/SARI systems, 

> active screening in hospitals and of groups that may be at higher occupational risk of exposure, and 

> inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

Vigilance for the emergence of novel influenza viruses with pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance


-- Notifying WHO 

All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{14} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{15} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{16}. Evidence of illness is not required for this report. Evidence of illness is not required for this report. 

WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions


-- Virus sharing and risk assessment 

It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{17} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA analyses will be published at http://www.who.int/teams/global-influenza-programme/avian-influenza/toolfor-influenza-pandemic-risk-assessment-(tipra).  


-- Risk reduction 

Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  

Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 


-- Trade and travellers 

WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

-- WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

-- WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

-- WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

-- WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

-- Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

-- Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

-- World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

-- Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

-- OFFLU http://www.offlu.org/ 

___

{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810

{6} World Health Organization. Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the International Health Regulations (2005). Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).   

{7} World Health Organization (5 December 2025). Disease Outbreak News; Avian Influenza A(H5N5)- United States of America. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2025DON590

{8} US CDC FluView. Weekly US Influenza Surveillance Report: Key Updates for Week 46, ending November 15, 2025. Available at https://www.cdc.gov/fluview/surveillance/2025-week-46.html

{9} Erdelyan CNG, Kandeil A, Signore AV, et al. Multiple transatlantic incursions of highly pathogenic avian influenza clade 2.3.4.4b A(H5N5) virus into North America and spillover to mammals. Cell Rep. 2024 Jul 23;43(7):114479. doi:10.1016/j.celrep.2024.114479. Epub 2024 Jul 13. PMID:39003741; PMCID:PMC11305400. 

{10}  World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{11} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en

{12} US CDC FluView. Weekly US Influenza Surveillance Report: Key Updates for Week 46, ending November 15, 2025. Available at https://www.cdc.gov/fluview/surveillance/2025-week-46.html

{13} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024. Available at: https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/

{14} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005). 

{15} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011). Available at: https://apps.who.int/iris/handle/10665/44518

{16} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition. Available at: https://iris.who.int/handle/10665/341850

{17} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017). Available at: https://apps.who.int/iris/handle/10665/259402

___

Source: 


Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--19-december-2025

____

Friday, November 21, 2025

#USA, Novel #Influenza A Virus #Infections: 1 case of #H5N5 and 1 case of #H1N2v detected (CDC, Nov. 21 '25)

 


{Excerpt}

Novel Influenza A Virus Infections

Two confirmed human infections with novel influenza A viruses were reported to CDC this week

One infection with an influenza A(H5N5) virus was reported by the Washington State Department of Health and one infection with an influenza A(H1N2) variant (A(H1N2)v) virus was reported by the Vermont Department of Health.

One infection with an influenza A(H5N5) virus was reported by the Washington State Department of Public Health

-- The case occurred in an individual aged ≥18 years

-- This individual developed symptoms during the week ending October 25, 2025 (Week 43) and was hospitalized with their illness during the week ending November 8, 2025 (Week 45). 

-- Respiratory specimens collected at the healthcare facility tested positive for influenza A and were presumptive positive for influenza A(H5) at the University of Washington. 

-- The specimens were sent to the Washington State Public Health Laboratory where influenza A(H5) was confirmed using the CDC influenza A(H5) assay. 

-- Sequencing conducted at the University of Washington and at the CDC indicated this was an influenza A(H5N5) virus.

-- The investigation by public health officials identified that the patient kept backyard poultry that had exposure to wild birds

-- The patient remains hospitalized

-- This is the twelfth confirmed influenza A(H5) case in Washington overall. 

-- Prior confirmed cases in Washington were associated with commercial poultry exposure. 

-- This is the 71st confirmed human case of A(H5) in the United States since early 2024 and the first human case reported in the United States since February 2025.

One infection with an influenza A(H1N2)v virus was reported by the Vermont Department of Health in an individual aged ≥18 years

-- The individual developed symptoms and sought healthcare during the week ending October 4, 2025 (Week 40), was hospitalized but discharged on the same day, and has recovered from their illness. 

-- The investigation conducted by state public health officials was unable to determine whether the individual had exposure to swine or other animals, or whether the patient's close contacts exhibited any illness. 

-- No human-to-human transmission has been identified associated with this case.

-- When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant” influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

(...)

Source: 


Link: https://www.cdc.gov/fluview/surveillance/2025-week-46.html

____

Monday, September 8, 2025

Continuous #evolution of #Eurasian #avian-like #H1N1 swine #influenza viruses with pdm/09-derived internal #genes enhances #pathogenicity in mice

 


ABSTRACT

Swine influenza A virus (swIAV) is an important zoonotic pathogen with the potential to cause human influenza pandemics. Swine are considered “mixing vessels” for generating novel reassortant influenza A viruses. In 2009, a swine-origin reassortant virus (2009 pandemic H1N1, pdm/09 H1N1) spilled over to humans, causing a global influenza pandemic. This virus soon spread back into swine herds and reassorted with the circulating swIAVs. We previously reported that the genotype 4 (G4) reassortant Eurasian avian-like (EA) H1N1 virus, which bore pdm/09- and triple reassortant (TR)-derived internal genes, had been predominant in swine populations of China since 2016, posing a threat to both the swine industry and public health. Here, our ongoing surveillance confirmed that G4 EA H1N1 viruses remained the predominant swIAVs in China from 2019 to 2023 and had reassorted with the co-circulating swIAVs, such as the H3N2 virus, to generate novel reassortant EA H1N2 viruses. Genetic analyses revealed that the pdm/09-derived internal genes of G4 EA H1N1 viruses originated from reassortments between pdm/09 H1N1 and EA H1N1 viruses in 2009–2010 and underwent independent and continuous evolution in the swine host, exhibiting higher evolutionary rates than those of the pdm/09 H1N1 virus circulating in humans. The accelerated evolution of internal genes enhanced the polymerase activity of G4 EA H1N1 viruses in mammalian cells, resulting in increased viral replication and pathogenicity in mice. This study provides evidence for swine in promoting the genetic evolution of influenza A virus and highlights the need for increased attention to novel reassortant viruses in swine.


IMPORTANCE

The emergence of pdm/09 H1N1 virus highlights the role of swine influenza A viruses (swIAVs) in generating novel influenza viruses with pandemic potential. Since 2009, the pdm/09 H1N1 virus has been frequently transmitted to swine and reassorted with the circulating swIAVs, generating many new reassortant viruses bearing pdm/09-derived genes globally. The G4 EA H1N1 viruses, which bore pdm/09-derived internal genes and acquired increased human infectivity, remained the predominant swIAVs in China from 2019 to 2023 and reassorted with the co-circulating swIAVs to generate novel subtype viruses. The internal genes of G4 EA H1N1 viruses originated from the human pdm/09 H1N1 viruses during 2009–2010 and exhibited higher evolutionary rates and greater genetic diversity than those in the human host. This has contributed to increased viral adaptation and pathogenicity in mammals. Therefore, sustained surveillance and immunization efforts are essential to control emerging reassortant swIAVs and protect public health.

Source: Journal of Virology, https://journals.asm.org/doi/10.1128/jvi.00430-25

____

Tuesday, August 26, 2025

#Sources and sinks of #influenza A virus genomic diversity in #swine from 2009 to 2022 in the #US

 


ABSTRACT

Influenza A virus (IAV) in swine in the U.S. is surveilled to monitor genetic evolution to inform intervention efforts and aid pandemic preparedness. We describe data from the U.S. Department of Agriculture National Surveillance Plan for Influenza A Virus in Pigs from 2009 to 2022. Clinical respiratory cases were subtyped, followed by sequencing of hemagglutinin (HA) and neuraminidase (NA), and a subset of viruses was whole genome sequenced. Phylogenetic analysis identified geographic and temporal IAV reassortment hotspots. Regions acting as IAV genomic diversity sources or sinks were quantified, and dissemination was qualified and modeled. The dominant IAV clades were H1N2 (1B.2.1), H3N2 (1990.4.a), and H1N1 (H1-1A.3.3.3-c3). Internal genes were classified as triple-reassortant (T) or pandemic 2009 (P), and three genome constellations represented 73.5% of detections across the last 2 years. In some years, the distribution of IAV diversity was so narrow that it presented a statistical signal associated with local adaptation. We also demonstrated that the source of most IAV genomic diversity was in Midwest states (IL, MO, IA), and while this was correlated with swine inventory, the emergence and persistence of diversity were tied to swine transport across the U.S. The continued regional detection of unique HA, NA, and genome constellations provides support for targeted interventions to improve animal health and enhance pandemic preparedness.


IMPORTANCE

Variation in the genetic diversity of influenza A virus (IAV) in swine through time and between regions impacts control efforts. This study quantified the genomic diversity of swine IAV collected from 2009 to 2022 at regional and national levels and modeled sources and sinks of that diversity. Seasonal patterns of IAV transmission were observed, and some locations contributed disproportionately to the emergence of genomic diversity. Minor groups of viruses had the potential to disseminate across the U.S. with animal movement. The identification of these patterns demonstrates the importance of a robust surveillance system to inform vaccine updates that reflect regional patterns of genetic diversity. We show how preemptive interventions in swine IAV diversity hubs could reduce reassortment and the emergence of novel genomic diversity, and how these efforts are likely to reduce the transmission of IAV within swine and between swine and humans.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00541-25?af=R

____

Monday, March 31, 2025

#Influenza at the #human - #animal #interface - #Summary and #risk #assessment, from 21 January to 19 March 2025 {WHO}



Influenza at the human-animal interface Summary and risk assessment, from 21 January to 19 March 2025{1} 


New human cases{2}: 

From 21 January to 19 March 2025, based on reporting date, the detection of influenza A(H5N1) in five humans, influenza A(H9N2) virus in four humans, influenza A(H1N1) variant ((H1N1)v) virus in one human, and influenza A(H1N2)v virus in one human were reported officially. 

Circulation of influenza viruses with zoonotic potential in animals: 

-- High pathogenicity avian influenza (HPAI) events in poultry and non-poultry continue to be reported to the World Organisation for Animal Health (WOAH).{3}  The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 

Risk assessment{5}: 

-- Sustained human to human transmission has not been reported from these events. Based on information available at the time of the risk assessment, the overall public health risk from currently known influenza viruses circulating at the human-animal interface has not changed remains low. The occurrence of sustained human-to-human transmission of these viruses is currently considered unlikely. Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  

Risk management

-- New candidate vaccine viruses (CVVs) for zoonotic influenza viruses for pandemic preparedness purposes were selected for development at the February 2025 WHO consultation on influenza vaccine composition for use in the northern hemisphere 2025-2026 influenza season. A detailed summary of zoonotic influenza viruses characterized since September 2024 is published here and updated CVVs lists are published here. 

IHR compliance

-- All human infections caused by a new influenza subtype are required to be reported under the International Health Regulations (IHR, 2005).{6} This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.


Avian influenza viruses in humans 

Current situation:  

Since the last risk assessment of 20 January 2025, one laboratory-confirmed human case of A(H5N1) infection was reported to WHO from Cambodia, one from the United Kingdom of Great Britain and Northern Ireland and three from the United States of America (USA).  

A(H5N1), Cambodia 

On 26 February 2025, Cambodia notified the WHO of a human case of influenza A(H5N1) in a boy from Prey Veng Province. The case had onset of fever, cough and fatigue on 17 February. He was initially seen at a local private clinic and given medication, but as his condition did not improve, he was transferred to Phnom Penh and hospitalized at a private hospital on 20 February. The case’s condition deteriorated, and he developed shortness of breath and was transferred on 24 February to a national hospital, which is a sentinel surveillance site for severe acute respiratory infection (SARI). Upon admission the case was isolated, nasopharyngeal (NP) and oropharyngeal (OP) swab specimens were collected and oseltamivir administered. On 25 February, the specimens tested positive for influenza A(H5N1) by reverse transcription-polymerase chain reaction (RT-PCR) at the National Institute of Public Health of Cambodia. The results were later confirmed by the Institut Pasteur du Cambodge (IPC) on 26 February. Sequence analysis of the HA gene revealed the virus belongs to clade 2.3.2.1e (previously classified as clade 2.3.2.1c){7}, and is similar to viruses circulating among birds, including poultry, and detected in human cases since late 2023 in Cambodia. The case was reported to have had exposure to sick and dead backyard chickens. Samples collected from the backyard chickens tested positive for A(H5N1). The case died on 25 February. No further cases were detected among the contacts of the case. This case is the second human infection with influenza A(H5N1) reported in Cambodia in 2025. 

A(H5N1), United Kingdom  

On 25 January 2025, the United Kingdom reported to WHO the detection of A(H5N1) in one individual in England who was sampled as part of a zoonotic influenza surveillance study launched by the UK Health Security Agency (UKHSA) in March 2023 to monitor people with close contact to infected birds. The individual was recruited to the surveillance study while working at a farm where birds were infected with A(H5N1) viruses and was found to be symptomatic. A sample collected on 23 January was confirmed A(H5)-positive at the national reference laboratory on 24 January. One symptomatic household contact tested negative. Sequencing of virus from the infected birds the case had contact with were determined to be of A(H5N1) clade 2.3.4.4b and the DI.2 genotype, which is prevalent within Europe at the current time. The DI.2 genotype is distinct from the A(H5) clade 2.3.4.4b genotypes that have been detected in North America.{8}  The UKHSA has previously notified WHO (in May, June, and July 2023) about four individuals who tested positive for influenza A(H5) virus as part of the UKHSA Zoonotic Influenza Surveillance Study.{9} 

A(H5N1), USA{10,11,12,13} 

In the USA, one laboratory-confirmed A(H5) infection was reported in an adult from the state of Ohio who worked at a commercial poultry facility where HPAI A(H5N1) virus had been detected in birds and was involved in depopulation activities. The individual had respiratory symptoms, was hospitalized, discharged and recovering at the time of the update. Genetic sequencing of the virus from this individual identified an avian influenza A(H5N1) virus from clade 2.3.4.4.b belonging to the genotype D1.3 genotype and no markers known that would impact the effectiveness of influenza antivirals or existing candidate vaccine viruses or changes associated with mammalian adaptation were identified.  Another laboratory-confirmed A(H5) infection was reported in an adult from the state of Wyoming who had direct contact with poultry infected with avian influenza A(H5) virus that died on their property. The individual was reported to have underlying health conditions that can be risk factors for severe influenza illness. This person has been discharged from the hospital and was recovering at the time of the update. Initial upper respiratory specimens were negative for influenza viruses; a lower respiratory specimen collected several days later in the hospital was positive for avian influenza A(H5N1) virus. Genetic sequencing of the virus from this individual identified an avian influenza A(H5N1) virus from clade 2.3.4.4.b belonging to the genotype D1.1, and the genetic mutation in the polymerase basic 2 (PB2) protein (E627K) that has previously been associated with more efficient virus replication in people and other mammals and has been detected in viruses from past human infections with A(H5) viruses.  Additionally, one laboratory-confirmed case was reported in an adult from the state of Nevada who worked at a commercial dairy cattle farm in an area where HPAI A(H5N1) viruses had been detected in cows. This individual developed conjunctivitis and recovered. Genetic sequencing of the virus from this individual identified an avian influenza A(H5N1) virus from clade 2.3.4.4.b also belonging to genotype D1.1, with a sequence nearly identical to that of the viruses that USDA reported from dairy cows in Nevada that the person worked with.{14} Sequencing also identified the D701N genetic mutation in the PB2 protein that has previously been associated with more efficient virus replication in mammalian cells and has been detected in viruses from past human infections with A(H5) viruses. Low pathogenicity and high pathogenicity avian influenza viruses have been detected in birds in the United States.  Since 2022, the HPAI A(H5) virus has been detected in commercial and backyard flocks in 48 states, impacting over 100 million birds. To date, 71 people have tested positive for A(H5) virus in the United States since 2022, with all but one of these cases occurring in 2024. All cases have been associated with exposure to either A(H5N1)-infected poultry or dairy cattle, except for two cases where the exposure source could not be identified.{15} To date, no human-to-human transmission of influenza A(H5) virus has been identified in the USA. A(H5N1) virus infections in dairy cattle and wild and domestic birds continue to be reported in the USA.{16} According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in the Americas, Asia and Europe. Infections in non-human mammals are also reported, including in marine and land mammals.{17} A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{18}


Risk Assessment for avian influenza A(H5) viruses:  

1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?  

-- Most human cases so far have been infections in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. While the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but unusual. The impact for public health if additional cases are detected is minimal. The current overall global public health risk of additional human cases is low. 

2. What is the likelihood of sustained human-to-human transmission of currently circulating avian influenza A(H5) viruses?  

-- No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5). There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.  Available evidence suggests that influenza A(H5) viruses circulating have not acquired the ability to efficiently transmit between people, therefore the likelihood of sustained human-to-human transmission is thus currently considered unlikely at this time.  

3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?  

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


A(H9N2), China 

Since the last risk assessment of 20 January 2025, four human cases of infection with A(H9N2) influenza viruses were notified to WHO from China on 7 February 2025. All four cases were detected through the influenza-like illness (ILI) surveillance system. The cases were detected in Guangdong (one), Hunan (two) and Sichuan (one) provinces. One case, in an adult, had underlying conditions at the time of illness and was hospitalized with pneumonia. The other cases (two children and one adult) had mild illnesses. Each case had a known history of exposure to poultry prior to the onset of symptoms. Environmental samples collected from areas associated with two cases (live poultry markets) tested positive for influenza A(H9) virus while samples from the environments associated with the other two cases (backyard areas) tested negative. No further cases were detected among contacts of these cases and there was no epidemiological link between the cases.  


Risk Assessment for avian influenza A(H9N2):  

1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?  

-- Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments. Most human infections of A(H9N2) to date have resulted in mild clinical illness in most cases. Nearly 130 human infections with A(H9N2) cases have been reported to date since 2003, and six of these have been severe or fatal and three of these were known to have underlying medical conditions. Since the virus is endemic in poultry in multiple continues in Africa and Asia{19}, further human cases associated with exposure to infected poultry are expected but remain unusual. The impact to public health if additional cases are detected is minimal. The overall global public health risk of additional human cases is low

2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses?  

-- At the present time, no sustained human-to-human transmission has been identified associated with the event described above. Current evidence suggests that influenza A(H9N2) viruses from these cases have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.  

3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?  

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.  


Swine Influenza Viruses   

Current situation:    

Since the last risk assessment of 20 January 2025, one detection of an influenza A(H1N1)v virus was reported from China and one detection of an influenza A(H1N2)v was reported from the USA.  


Influenza A(H1N1)v, China 

On 7 February 2025, China notified WHO of a human case of Eurasian avian-like swine influenza A(H1N1) virus in a child from Yunnan Province. She developed mild upper respiratory tract symptoms on 12 November 2024 and a respiratory sample was collected on 13 November 2024 as part of routine influenza-like illness (ILI) surveillance. Close contacts remained asymptomatic and tested negative for influenza. She had exposure to backyard pigs however samples collected from the pigs tested negative for Eurasian avian-like swine influenza A(H1N1) viruses. The virus from this case was a clade 1C.2.3 virus. 


Influenza A(H1N2)v, USA  

A laboratory-confirmed human infection with an influenza A(H1N2)v virus was reported in an adult from the state of Iowa. The individual sought health care during the week ending 18 January 2025, was hospitalized, and recovered. An investigation by public health officials did not identify direct or indirect swine contact. No further cases were identified associated with this case. The virus from this case belonged to clade 1B.2.1 which is known to circulate in swine in the USA. 


Risk Assessment:   

1. What is the public health risk of additional human cases of infection with swine influenza viruses?    

-- Swine influenza viruses circulate in swine populations in many regions of the world. Depending on geographic location, the genetic characteristics of these viruses differ. Most human cases are exposed to swine influenza viruses through contact with infected animals or contaminated environments. Human infection tends to result in mild clinical illness in most cases. Since these viruses continue to be detected in swine populations, further human cases are expected but remain unusual. The impact for public health if additional cases are detected is minimal. The overall risk of additional human cases is low.    

2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses?    

-- No sustained human-to-human transmission was identified associated with the events described above. Current evidence suggests that contemporary swine influenza viruses have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.     

3. What is the likelihood of international spread of swine influenza viruses by travelers?    

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. If this were to occur, further community level spread is considered unlikely as current evidence suggest that these viruses have not acquired the ability to transmit easily among humans.   

For more information on zoonotic viruses, see the report from the WHO Consultation on the Composition of Influenza Virus Vaccines for Use in the 2025-2026 Northern Hemisphere Influenza Season held on 24-27 February 2025 at the following link: Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness in the 2025-2026 northern hemisphere influenza season.  


Overall risk management recommendations

Surveillance and investigations 

• Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. 

• As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

• Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, share genetic sequences of avian influenza viruses in publicly available databases, implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{20}  

• When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: enhanced surveillance in local influenza-like illness (ILI)/SARI systems, active screening in hospitals and of groups that may be at higher occupational risk of exposure, and inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

• Vigilance for the emergence of novel influenza viruses of pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance. Notifying WHO 

• All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{21} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{22} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{23}. Evidence of illness is not required for this report. 

• WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions. 


Virus sharing and risk assessment 

• It is critical that these influenza viruses from animals or from people are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{24} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

• The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA analyses will be published at http://www.who.int/teams/global-influenza-programme/avian-influenza/toolfor-influenza-pandemic-risk-assessment-(tipra).  


Risk reduction 

• Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  

• Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

• WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 


Trade and travellers 

• WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

• WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

-- WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

-- WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

-- WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

-- WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

-- Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

-- Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

-- World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

-- Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

-- OFFLU http://www.offlu.org/ 

____

{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2. 

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential. 

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810. 

{6} World Health Organization. Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the International Health Regulations (2005). Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).   

{7} Ort JT, Zolnoski SA, Lam TT, Neher R, Moncla LH. Development of avian influenza A(H5) virus datasets for Nextclade enables rapid and accurate clade assignment. bioRxiv [Preprint]. 2025 Feb 3:2025.01.07.631789. doi: 10.1101/2025.01.07.631789. PMID: 39829835; PMCID: PMC11741357. 

{8} UKHSA. Human case of avian flu detected in England, 27 January 2025. Available at: https://www.gov.uk/government/news/human-case-of-avian-flu-detected-in-england. 

{9} UKHSA. Investigation into the risk to human health of avian influenza (influenza A H5N1) in England: technical briefing 5, Updated 14 July 2023. Available at: https://www.gov.uk/government/publications/avian-influenzainfluenza-a-h5n1-technical-briefings/investigation-into-the-risk-to-human-health-of-avian-influenza-influenzaa-h5n1-in-england-technical-briefing-5. 

{10} US CDC. Weekly US Influenza Surveillance Report: Key Updates for Week 6, ending February 8, 2025. Available at: https://www.cdc.gov/fluview/surveillance/2025-week-06.html. 

{11} US CDC. Weekly US Influenza Surveillance Report: Key Updates for Week 7, ending February 15, 2025. Available at:  https://www.cdc.gov/fluview/surveillance/2025-week-07.html. 

{12} US CDC. CDC A(H5N1) Bird Flu Response Update, February 26, 2025. Available at: https://www.cdc.gov/birdflu/spotlights/h5n1-response-02262025.html. 

{13} US CDC. CDC A(H5N1) Bird Flu Response Update March 19, 2025. Available at https://www.cdc.gov/birdflu/spotlights/h5n1-response-03192025.html. 

{14} USDA. The Occurrence of Another Highly Pathogenic Avian Influenza (HPAI) Spillover from Wild Birds into Dairy Cattle. Available at:https://www.aphis.usda.gov/sites/default/files/dairy-cattle-hpaitech-brief.pdf 

{15} United States Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. Available at: https://www.cdc.gov/bird-flu/situationsummary/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fbird-flu%2Fphp%2Favian-flusummary%2Findex.html. 

{16}  United States Department of Agriculture. Highly Pathogenic Avian Influenza (HPAI) Detections in Livestock, 19 July 2024. Available at: https://www.aphis.usda.gov/livestock-poultry-disease/avian/avian-influenza/hpaidetections/livestock. 

{17}  World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2. 

{18} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en. 

{19} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential. 

{20} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024. Available at: https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/. 

{21} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).    

{22} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011). Available at: https://apps.who.int/iris/handle/10665/44518 

{23} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition. Available at: https://iris.who.int/handle/10665/341850 

{24} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017). Available at: https://apps.who.int/iris/handle/10665/25940 

Source: World Health Organization, https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment-19-march-2025

____

My New Space

Most Popular Posts